Benzinga | Aug 18, 2021 06:24AM EDT

HC Wainwright & Co. Maintains Buy on Freeline Therapeutics, Lowers Price Target to $20

HC Wainwright & Co. analyst Patrick Trucchio maintains Freeline Therapeutics (NASDAQ:FRLN) with a Buy and lowers the price target from $30 to $20.